Assessment of Access Barriers to Rifaximin Among Patients with Hepatic Encephalopathy Using Adjudicated Claims Data
Prescription claim rejections frequently led to delays in rifaximin initiation and gaps in access during active treatment. Access barriers to rifaximin were associated with increased hospitalizations and healthcare costs in patients with HE.
Authors
- Jessica Maitland (ORCID: https://orcid.org/0009-0002-6804-319X)
- Olamide Olujohungbe
- Brock Bumpass
- Kana Yokoji
- Zeev Heimanson
- Arun Jesudian (ORCID: https://orcid.org/0000-0002-8562-3375)
- Patrick Gagnon‐Sanschagrin (ORCID: https://orcid.org/0000-0002-3582-9447)
- Aaron Samson
- Annie Guérin
Institutions
- Cornell University (US)
- Bausch Health (United States) (US)
- Epix Pharmaceuticals (United States) (US)
- Group for Research in Decision Analysis (CA)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1007/s12325-025-03145-3
- Citations
- 2
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- Bausch Health